Managed Access Programmes


The FarmaMondo Group supports biopharmaceutical companies in the supply of products to patients in markets where they have not yet been launched commercially. We design and implement Managed Access Programmes (MAP), including Named Patient Programmes (NPP) services, in more than 80 markets.

While the market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric approach also allows access for patients with unmet medical needs in countries where their therapies are not yet commercially available.

It may take years before therapies are approved for commercial supply in certain countries, and patients cannot always wait that long. During this lag time, FarmaMondo responds to global healthcare professionals’ requests to access such therapies and supplies them with country-specific named patient regulatory routes.

The Group offers both paid access and pro-bono (compassionate) access programmes through a comprehensive service package with a fair financial structure and flexible terms.

Via our footprint and granular market access expertise, we utilize paid access Named Patient pathways through our comprehensive service package based on flexible commercial terms.

The Group currently operates the following programmes across various geographic regions. For more information, please contact FarmaMondo offices in your region or our Medical Affairs team

Therapeutic Area Indications Geographical Scope
CardiovascularAcute Ischemic StrokeTargeted regions/countries
Acute Myocardial infarctionTargeted regions/countries
Arterial HypertensionTargeted regions/countries
Idiopathic or heritable pulmonary arterial hypertension (PAH)Targeted regions/countries
Infectious Diseases & VirologyViral CMV retinitis; Mucocutaneous Acyclovir Resistant HSV InfectionsTargeted regions/countries
Metabolic Disease OrphanWilson's disease (orphan)Targeted regions/countries
Congenital or Acquired Generalized LipodystrophyTargeted regions/countries
Homozygous Familial HypercholesterolemiaTargeted regions/countries
Gaucher DiseaseGlobal
Alagille syndrome (ALGS)Targeted regions/countries
Progressive familial intrahepatic cholestasis (PFIC)Targeted regions/countries
Neurology OrphanDuchenne Muscular DystrophyTargeted regions/countries
NeurologyEpilepsyTargeted regions/countries
OncologyEpithelial ovarian cancer / fallopian tube cancerTargeted regions/countries
Chemotherapy induced neutropeniaTargeted regions/countries
Onco-haematologyAcute Promyelocytic LeukemiaTargeted regions/countries
Multiple myelomaTargeted regions/countries
Acute Lymphoblastic Leukemia (ALL)Global
Ophthalmology OrphanNeurotrophic KeratitisTargeted regions/countries
Pediatric OncologyNeuroblastomaTargeted regions/countries
TransplantationConditioning agent for bone marrow transplantationTargeted regions/countries
Dermatology/OrphanEpidermolysis Bullosa (EB) Targeted regions/countries


  • If you would like to send us a general enquiry, please complete the following form.